Published in final edited form as:

J Am Chem Soc. 2009 August 5; 131(30): 10376–10377. doi:10.1021/ja9042824.

Biosynthesis of Salinosporamides from α,β -Unsaturated Fatty Acids: Implications for Extending Polyketide Synthase Diversity

Yuan Liu[†], Christopher Hazzard[‡], Alessandra S. Eustáquio[†], Kevin A. Reynolds[‡], and Bradley S. Moore^{†,§}

[†]Scripps Institution of Oceanography, University of California at San Diego, La Jolla, CA 92093-0204

[§]Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, La Jolla, CA 92093-0204

[‡]Department of Chemistry, Portland State University, Portland, OR 97207-0751

The salinosporamides comprise a natural product family of potent anticancer agents produced by the marine bacterium *Salinispora tropica*. This group of densely functionalized β -lactone- γ -lactam proteasome inhibitors is largely distinguished through structural differences at C-2 bearing methyl, ethyl, chloroethyl, and propyl substituents per salinosporamides D (**1**), B (**2**), A (**3**) and E (**4**), respectively (Scheme 1).¹⁻³ The recent discovery of the related metabolite cinnabaramide A (**5**) from a terrestrial streptomycete,⁴ which instead harbors a C-2 hexyl chain, further extends the natural salinosporamide structural family. We recently reported that salinosporamides A and B are biosynthetic products derived from an unusual hybrid polyketide synthase-nonribosomal peptide synthetase (PKS-NRPS) pathway initiated by the chain elongation of acetyl-S~ACP by chloroethylmalonyl-CoA or ethylmalonyl-CoA,^{5,6} respectively, followed by the non-proteinogenic amino acid cyclohexenylalanine (Scheme 1).⁷ The selection of the PKS extender unit is controlled by the acyltransferase domain AT₁ from the hexadomained SalA synthase. Herein we report that salinosporamides D and E are respectively accessed from methylmalonyl-CoA and propylmalonyl-CoA, the latter of which is a newly described PKS extender unit that belongs to a growing family of PKS substrates derived from α,β -unsaturated fatty acids.

Based on the biosynthetic assembly of salinosporamide B from a butyrate building block via ethylmalonyl-CoA,^{5,6} we reasoned that the methyl analog salinosporamide D (**1**) would be similarly assembled from a propionate unit via the common PKS substrate (2*S*)-methylmalonyl-CoA (Scheme 1). We explored this assumption by administering [1-¹³C] propionate to the *S. tropica salL*-deficient mutant, which is specifically unable to synthesize the chlorinated salinosporamide A as the major product of the *sal* pathway due to inactivated 5'-chloro-5'-deoxyadenosine synthase SalL.⁸ Isolation and characterization of the resultant salinosporamide D by NMR revealed the specific ¹³C-enrichment (5%) at C-1, thereby confirming its assembly from propionate.

We next turned our attention to the propyl analog salinosporamide E (**4**), which would presumably derive from a pentanoate building block. If so, this would imply the prospect of a new PKS building block, namely propylmalonyl-CoA. Salinosporamide E was similarly isolated from the [1-¹³C]propionate feeding experiment, and NMR analysis confirmed ¹³C-enrichment (40%) at C-12, thereby suggesting an origin from pentanoate derived from

bsmoore@ucsd.edu.

Supporting Information Available: Experimental procedures, NMR data and SalG kinetic data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

propionate and acetate precursors (Scheme 1). While the administration of pentanoic acid to the *S. tropica salL*-deficient mutant resulted in a significant increase (~500%) in salinosporamide E titers, unsaturated *trans*-2-pentenoic acid had a much greater effect in enhancing its production at ~1500% (Figure 1). These observations suggested that the C₅ substrate is limiting and that the α,β -unsaturated carboxylic acid is a more advanced biosynthetic intermediate.

The recent functional revision of crotonyl-CoA reductase (CCR) as a carboxylase that catalyzes the reductive carboxylation of crotonyl-CoA to (2*S*)-ethylmalonyl-CoA⁹ suggests the possibility of an analogous pathway to (2*S*)-propylmalonyl-CoA in *S. tropica* from 2-pentenyl-CoA (Scheme 1). Inspection of the complete genome sequence of *S. tropica* CNB-440¹⁰ revealed two CCR-encoding genes. We previously inactivated each by PCR-targeted mutagenesis and showed that Strop_3612 encodes a primary CCR involved in salinosporamide B biosynthesis while the homolog *salG* codes for a novel chlorocrotonyl-CoA reductase/carboxylase associated with salinosporamide A biosynthesis.⁶ Upon further analysis of the *S. tropica* CCR mutants, we observed that production of salinosporamide E was exclusively lost in the *salG* knockout mutant whereas it was maintained in the Strop_3612 mutant (Figure 1). Hence, this in vivo experiment suggests that SalG has relaxed substrate specificity towards 2-alkenyl-CoAs and is able to also reductively carboxylate 2-pentenyl-CoA in addition to 4-chlorocrotonyl-CoA as previously reported.⁶ In vitro analysis of recombinant octahistidyl-tagged SalG confirmed that it is able to reductively carboxylate 2-pentenyl-CoA (k_{cat} 25.5 $\pm$ 0.7 min⁻¹; K_m 4.3 $\pm$ 0.5 μ M) at comparable efficiency to 4-chlorocrotonyl-CoA (k_{cat} 23.1 $\pm$ 2.6 min⁻¹; K_m 4.4 $\pm$ 1.8 μ M), which is more efficient than that with crotonyl-CoA (k_{cat} 15.4 $\pm$ 0.9 min⁻¹; K_m 20.7 $\pm$ 4.2 μ M).⁶ Presumably, the CCR encoded by Strop_3612 has more substrate specificity towards crotonyl-CoA, although attempts to verify this hypothesis were unsuccessful due to issues with soluble expression of the protein. However, we did observe in parallel experiments that the CCR originally isolated from *Streptomyces collinus*¹¹ uses crotonyl-CoA and not 2-pentenyl-CoA as a substrate for reductive carboxylation. Thus this CCR and SalG have markedly different substrate specificities yet likely have the same 2*S*-stereochemical outcome as in other homologous CCRs and medium-chain dehydrogenases/reductases.⁹

Given the relaxed in vitro and in vivo substrate specificity of SalG, we explored other substrates including 4-bromo- and 4-fluorocrotonate, which are anticipated substrates of natural bromosalinosporamide (**6**)³ and engineered fluorosalinosporamide (**7**),¹² respectively (Scheme 1). Administration of the 4-halocrotonic acids to the *S. tropica salL*-deficient mutant resulted in the production of **6** and **7** as anticipated (Figure 1), thereby establishing bromoethylmalonyl-CoA and fluoroethylmalonyl-CoA as additional PKS extender units unique to the salinosporamide biosynthetic pathway. While the 4-halo analogs were accepted as alternative in vivo substrates,¹³ elongated 2-alkenoates (C₆ to C₈) were not converted into new *sal* products as observed by HPLC-MS analysis. The capacity of a CCR homolog to preferentially accommodate a longer chain 2-alkenyl-CoA, however, is strongly suggestive in the biosynthesis of cinnabaramide A (**5**),⁴ which based on the salinosporamide biosynthetic model would incorporate (2*S*)-hexylmalonyl-CoA derived from the reductive carboxylation of 2-octenyl-CoA.

In conclusion, we discovered the new PKS extender unit propylmalonyl-CoA, in the context of salinosporamide E biosynthesis. It is rare for PKSs to incorporate pentyl building blocks in their polyketide products; to our knowledge only the macrolide immunosuppressant FK506,¹⁴ which carries an allyl side chain, and the acyl depsipeptide dentigerumycin¹⁵ may similarly incorporate propylmalonyl-CoA units. This discovery exemplifies a new strategy in PKS extender unit biochemistry in which α,β -unsaturated acyl-CoA thioesters are reductively

carboxylated¹⁶ and furthermore suggests that CCR protein engineering may readily afford unnatural malonyl-CoA precursors for the bioengineering of novel polyketide molecules.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge valuable discussions with Prof. Yoshihisa Kobayashi (UCSD) and financial support provided by the National Institutes of Health (CA127622 to B.S.M. and AI51629 to K.A.R.) and the Life Sciences Research Foundation via a Tularik postdoctoral fellowship to A.S.E.

References

- (1). Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W. *Angew. Chem. Int. Ed* 2003;115:369–371.
- (2). Williams PG, Buchanan GO, Feling RH, Kauffman CA, Jensen PR, Fenical W. *J. Org. Chem* 2005;70:6196–6203. [PubMed: 16050677]
- (3). Reed KA, Manam RR, Mitchell SS, Xu J, Teisan S, Chao TH, Deyanat-Yazdi G, Neuteboom ST, Lam KS, Potts BC. *J. Nat. Prod* 2007;70:269–276. [PubMed: 17243724]
- (4). Stadler M, Bitzer J, Mayer-Bartschmid A, Müller H, Benet-Buchholz J, Gantner F, Tichy H-V, Reinemer P, Baco KB. *J. Nat. Prod* 2007;70:246–252. [PubMed: 17249727]
- (5). Beer LL, Moore BS. *Org. Lett* 2007;9:845–848. [PubMed: 17274624]
- (6). Eustáquio AS, McGlinchey RP, Liu Y, Hazzard C, Beer LL, Florova G, Alhamadsheh MM, Lechner A, Kale AJ, Kobayashi Y, Reynolds KA, Moore BS. *Proc. Natl. Acad. Sci. U.S.A.* in press
- (7). McGlinchey RP, Nett M, Eustáquio AS, Asolkar RN, Fenical W, Moore BS. *J. Am. Chem. Soc* 2008;130:7822–7823. [PubMed: 18512922]
- (8). Eustáquio AS, Pojer F, Noel JP, Moore BS. *Nat. Chem. Biol* 2008;4:69–74. [PubMed: 18059261]
- (9). Erb TJ, Berg IA, Brecht V, Müller M, Fuchs G, Alber BE. *Proc. Natl. Acad. Sci. U.S.A* 2007;104:10631–10636. [PubMed: 17548827] Erb TJ, Brecht V, Fuchs G, Müller M, Alber BE. *Proc. Natl. Acad. Sci. U.S.A* 2009;106:8877–8882. [PubMed: 19470640]
- (10). Udway DW, Zeigler L, Asolkar RN, Singan V, Lapidus A, Fenical W, Jensen PR, Moore BS. *Proc. Natl. Acad. Sci. U.S.A* 2007;104:10376–10381. [PubMed: 17563368] Penn K, Jenkins C, Nett M, Udway DW, Gontang EA, McGlinchey RP, Foster B, Lapidus A, Podell S, Allen EE, Moore BS, Jensen PR. *ISME J.* 2009doi: 10.1038/ismej.2009.58
- (11). Wallace KK, Bao ZY, Dai H, Digate R, Schuler G, Speedie MK, Reynolds KA. *Eur. J. Biochem* 1995;233:954–962. [PubMed: 8521864]
- (12). Eustáquio AS, Moore BS. *Angew. Chem. Int. Ed* 2008;47:3936–3938.
- (13). Administration of 4-bromocrotonic acid to the *S. tropica salL*[−] mutant also provided the chlorinated **3** (Figure 1, trace G) as a minor product. Its production presumably derives from the transchlorination of the substrate in the seawater-based A1 medium.
- (14). Motamedi H, Shafiee A. *Eur. J. Biochem* 1998;256:528–534. [PubMed: 9780228]
- (15). Oh D-C, Poulsen M, Currie CR, Clardy J. *Nat. Chem. Biol* 2009;5:391–393. [PubMed: 19330011]
- (16). Chan YA, Podevels AM, Kevany BM, Thomas MG. *Nat. Prod. Rep* 2009;26:90–114. [PubMed: 19374124]

Scheme 1.

Biosynthesis of salinosporamide A (3), its analogs and their substituted malonyl-CoA PKS building blocks (boxed). Abbreviations: ACP, acyl carrier protein; KS, ketosynthase; AT, acyltransferase; C, condensing domain; A, adenylation domain; PCP, peptidyl carrier protein.

Figure 1.

HPLC analysis at 210 nm of organic fractions of (A) wild-type *S. tropica*, (B) *S. tropicasalL*⁻ mutant, (C) *S. tropica* Strop_3612⁻ mutant (D) *S. tropicasalG*⁻ mutant, (E) *S. tropicasalL*⁻ + 0.8 mM pentanoic acid, (F) *S. tropicasalL*⁻ + 0.8 mM *trans*-2-pentenoic acid, (G) *S. tropicasalL*⁻ + 0.12 mM 4-bromocrotonoic acid, and (H) *S. tropicasalL*⁻ + 0.15 mM 4-fluorocrotonoic acid. Salinosporamide analogs **1-4** and **6-7** are noted, while derivatives of **3** are marked with an asterisk.